Your Cells' Power Plants Can Now Be Replaced — Inside Any Organ

Every cell in your body runs on microscopic batteries called mitochondria. When those batteries fail — in the heart, the brain, or the retina — whole organs start to die. And for millions of people, that failure is untreatable. Now a team of researchers in Switzerland has built something wild: a delivery system that transplants healthy mitochondria directly into diseased cells, and nothing else. They call it MitoCatch.

The Invisible Blackout Inside Your Cells

Mitochondrial dysfunction is not some rare footnote. It drives Parkinson’s, heart failure, Leber’s hereditary optic neuropathy (a form of sudden blindness), and even some age-related muscle loss. For decades, doctors could only watch. The idea of transplanting healthy mitochondria has been around, but it was brutally blunt — like throwing a bucket of spare parts into an engine and hoping the right piston lands in the right cylinder. Most of the time, the wrong cells swallowed the cargo, or nothing happened at all.

Why Old Mitochondria Transplants Failed

Earlier attempts just dumped mitochondria into the bloodstream or tissue. They entered cells randomly — mostly liver or immune cells — and rarely reached the specific neurons or heart muscle that were actually dying. You’d need huge amounts, and most of the cargo went to waste. Worse, sometimes the recipient’s immune system attacked the foreign mitochondria. The field stalled. No precision, no therapy.

How Does MitoCatch Actually Work? (It's Like a Key and Lock)

The team at the Institute of Molecular and Clinical Ophthalmology Basel designed three ways to make mitochondria stick only to the right cells. One method: attach a tiny “grabber” (a nanobody) on the surface of the damaged cell. Another: put the grabber directly on the donor mitochondria. The third uses a double-sided connector that links both. Think of a delivery drone that only unlocks at one address. In human neurons grown in a dish, the system delivered fresh mitochondria to nine out of ten target cells, while ignoring neighbours. Here’s the interesting part: once inside, the transplanted mitochondria started moving, fusing with the cell’s own sick mitochondria, and even dividing — just like natural ones.

In a telling experiment, researchers used a strain of neurons from a patient with Leber’s optic neuropathy — a genetic error that blinds young adults. Those neurons normally die in sugar-free conditions. After MitoCatch delivery, survival jumped 23.6%. The cells’ oxygen consumption (a measure of energy production) nearly doubled. The mitochondria worked.

What This Means for Real People — Especially in India

India has one of the highest rates of undiagnosed mitochondrial disorders, partly because genetic testing is expensive and specialist centres are few. Kids with unexplained weakness, cardiomyopathy, or progressive vision loss often go through years of futile treatments. MitoCatch isn't ready for clinics yet, but the principle is huge: a therapy that can be tuned to any cell type by swapping a protein binder. That means the same platform might one day treat retinal degeneration in Bangalore, heart failure in Mumbai, or even post-stroke brain damage anywhere.

Globally, the approach worked on human cardiac cells, T-cells, and endothelial cells — the lining of blood vessels. In mice with crushed optic nerves (mimicking traumatic injury), targeted mitochondria saved 46% more retinal ganglion cells. Those are the cells that send vision signals to the brain.

The Road Ahead: Limits and Human Trials

Of course, there are caveats. Most experiments were done in dishes or mice. We don’t know how long the transplanted mitochondria last in a human body. The delivery currently requires an injection — fine for eyes or local tissue, harder for whole organs. And while no immune reaction was seen in mice, human immune systems are more complicated. The team is already working on higher-affinity binders to lower the required dose. The next step? Large-animal studies, then safety trials. But the door is open. For the first time, we can replace a cell’s power plant without rewiring the whole neighbourhood.

• Pinpoint accuracy — MitoCatch uses molecular “keys” to target only the sick cells, leaving healthy ones alone.
• Works across tissues — Tested on neurons, heart cells, immune cells, and blood vessel lining. One platform, many diseases.
• Mitochondria behave normally — Inside the host cell, donated mitochondria move, fuse, and divide as if they belong there.

"Mitochondrial delivery in its current form has low efficiency and cannot be targeted to disease-affected cell types. MitoCatch solves both." — Authors, Nature 2026.